GlassScriptPhysician profile
Christopher R Bowman
NPI 1770842759
$14,409.26
in general payments reported to CMS, 2019-2025
34 companies · $2,497 in 2025
The $2,497 reported for 2025 was more than what 80% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,427 · 2020: $1,592 · 2021: $2,298 · 2022: $2,302 · 2023: $2,362 · 2024: $1,931 · 2025: $2,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,748 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,747.92 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,379.67 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Lilly USA, LLC | $2,266.06 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,885.62 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,233.81 | 2019-2024 | Farxiga |
| Corcept Therapeutics | $901.58 | 2019-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $684.96 | 2019-2025 | |
| Abbott Laboratories | $559.59 | 2021-2025 | Freestyle Libre 3 |
| Insulet Corporation | $552.90 | 2019-2025 | Omnipod |
| Mannkind Corporation | $550.86 | 2021-2025 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $534.93 | 2020-2025 | Jardiance, Synjardy |
| Xeris Pharmaceuticals, INC. | $444.25 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Cequr Corporation | $373.59 | 2024-2025 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $249.38 | 2022-2025 | |
| Tandem Diabetes Care, INC. | $230.22 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $209.95 | 2023-2025 | Minimed 780g |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $167.79 | 2025 | Twiist |
| Abbvie INC. | $156.85 | 2020-2025 | Synthroid |
| Dexcom, INC. | $154.80 | 2023-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.55 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $131.71 | 2022-2024 | |
| Beta Bionics, INC. | $126.18 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Radius Health, INC. | $78.09 | 2020-2025 | Tymlos |
| Glaxosmithkline, LLC. | $72.69 | 2025 | Arexvy, Shingrix |
| Amneal Pharmaceuticals LLC | $59.00 | 2024-2025 | Unithroid |
| Ascendis Pharma Endocrinology INC | $43.11 | 2025 | Yorvipath |
| Esperion Therapeutics, INC. | $38.90 | 2020-2022 | |
| Medtronic Minimed, INC. | $37.22 | 2019 | |
| Olympus America INC. | $28.31 | 2023 | |
| Merck Sharp & Dohme LLC | $25.30 | 2019 | |
| Ibsa Pharma INC. | $22.58 | 2025 | Licart, Flector, Tirosint |
| Companion Medical, INC. | $18.33 | 2019 | |
| Zealand Pharma US, INC. | $17.37 | 2022 | |
| Lifescan, INC. | $16.28 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $14.83 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.